6492 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. It has two agents in clinical development for cancer, which includes CX-5461, a compound that activates p53 and kills cancer cells; and CX-4945, a compound that controls the growth and proliferation of cancer cells. The company was founded by Tai Sen Soong on November 16, 2012 and is headquartered in New Taipei, Taiwan.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
6492 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company